Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence.
The epidemic of obesity experienced in both industrialized and nonindustrialized countries largely accounts for the increase in the prevalence of the cardiometabolic syndrome (CMS). Obesity and the CMS significantly increase the risk for cardiovascular disease (CVD) and chronic kidney disease (CKD). Multiple abnormalities that can lead to kidney injury have been identified in overweight and obese people, including insulin resistance, compensatory hyperinsulinemia, inappropriate activation of the renin-angiotensin-aldosterone system and increased oxidative stress, endoplasmic reticulum stress, coagulability, and impaired fibrinolysis. The combined effects of these conditions induce in the kidneys impaired pressure natriuresis, glomerular hypertension, endothelial dysfunction, and vasoconstriction, as well as matrix proliferation and expansion. Among the consequences are microalbuminuria, now known to be a surrogate of diffuse endothelial dysfunction as well as a predictor of CVD, and CKD. Diet and regular physical activity are the cornerstones of weight management, and they add to currently available pharmacologic agents and bariatric surgery. The understanding of the pathophysiology of obesity/CMS helps to explain the benefits of agents that improve insulin sensitivity, control inflammation, and block the renin-angiotensin-aldosterone system. The increasing prevalence of obesity and CMS contribute to the growing frequency of CKD and demands the development of multifactorial strategies directed at identifying people at risk, as well as preventing excessive weight gain and its deleterious consequences.